alessio aghemo first division of gastroenterology fondazione irccs ca’ granda, ospedale maggiore...
TRANSCRIPT
Alessio AghemoFirst Division of GastroenterologyFondazione IRCCS Ca’ Granda, Ospedale Maggiore PoliclinicoUniversità degli Studi di Milano
5th Paris Hepatitis C Conference
Paris, 30 January 2012
Luncheon: How to optimize treatment of G2 and G3 patients
HCV infection (genotype 2a/c) known since 1998
No risk factors for HCV ALT values 2 x ULN since 1998Comorbidities: overweight (BMI 28)
September 2008:Fibroscan 10.2 KPa, SR 96%, IQR 1.1Enlarged liver at US, no splenomegalyRefuses PegIFN plus Rbv
Continues Follow-up visits at our center
S.G. 57 yr Housewife
• ALT IU/L 61• HCV-RNA 105/IU/mL 2.68
• Total Bilirubin mg/dL 1.2• Albumin g/dL 4.1• Prothrombin ratio 1.12• Platelets 103/mmc 195
• Fibroscan KPa 10.2
1125.62
1.03.9
1.11196
9.8
783.62
1.04.0
1.16184
11.4
Sep 2008 Sep 2010Sep 2009
Liver Function Tests
Liver Function
Liver biopsy: 24 mm specimen Chronic hepatitis with septae (Ishak G7, S4)
• ALT IU/L 78• HCV-RNA 105/IU/mL 3.68
• Total Bilirubin mg/dL 1.0• Albumin g/dL 4.1• Prothrombin ratio 1.12• Platelets 103/mmc 195
• Hb 14• WBC 5500• Neutrophils 2900
33<12
1.03.9
1.11127
12.541301630
39ND
0.93.9
1.16118
11.835001450
Baseline Week 4Week 2
Liver Function Tests During PegIFNalfa2a 180 mcg
+ Rbv 800 mg/day
Liver Function
What is the optimal treatment duration?
HCV RNA Kinetics During PegIFN + Rbv to Predict Treatment Outcome and Individualize Treatment Duration
HCV-2/3 Patients
Weeks 0 12-16 24
PegIFNalfa + RBV 800/dayPegIFNalfa + RBV 800 mg/day
Design No. Regimen Duration RVR (LOD)
Allocation by RVR
Dalgard 2004 122 Peg2b + Rbv wbd 14 w 78% (50 IU)
Mangia 2005 283 Peg2b 1.0 + Rbv wbd 12 w 63% (50 IU)
Randomization by RVR
von Wagner 2005 153 Peg2a + Rbv wbd 16 w 93% (600 IU)
Dalgard 2008 428 Peg2b + Rbv wbd 14 w 71% (50 IU)
Baseline Randomization
Shiffman 2007 1469 Peg2a + Rbv 800 mg 16 w 65% (50 IU)
Lagging 2008 382 Peg2a + Rbv 800 mg 12 w 60% (15 IU)
SVR Rates Following Abbreviated Therapy in HCV-2 and HCV-3
RVR (+) RVR (-)
50%
67%
-
75%
RVR (+)
Standard (24 weeks)Abbreviated (12-16 weeks)
91%
87%
95%
93%
-
89%
95%
97%
HCV-2 only
65% 65%82%
71%
0%
20%
40%
60%
80%
100%
Genotype 2 Genotype 3
16 weeks Pegasys 180 ug + Copegus 800 mg24 weeks Pegasys 180 ug + Copegus 800 mg
The ACCELERATE Study: SVR Rates by GenotypeS
VR
(%
)
Standard population; VR = HCV RNA < 50 IU/mL
N=346 N=303 N=333 N=327
P= <.0001 P= 0.1565
60%
70%77%
86%
60%
70%
66%
76%
White lines represent 95% confidence intervals
Shiffman ML et al NEJM 2007 Jul 12;357(2):124-34.
The ACCELERATE Study: sub-analysis of SVR in Patients with RVR
N=215
SVRSVR
p=0.0012
p=0.1046
92%
90%
81%
84%
0% 20% 40% 60% 80% 100%
Genotype 3
Genotype 2
16 weeks Pegasys 180 ug + Copegus 800 mg
24 weeks Pegasys 180 ug + Copegus 800 mg
N=243
N=212
N=193
Shiffman ML et al NEJM 2007 Jul 12;357(2):124-34.
Identifying HCV-2/3 Patients Who Can Receive a 16-wk Abbreviated Course of PegIFNalfa2a and Ribavirin
Similar SVR rates 87% vs 88% in patients with at least 2 positive predictors LVL, <40 yrs, <65 Kg and absence of cirrhosis
Diago M et al, Hepatology 2010 ; 51(6):1897-903
Efficacy of PegIFNalfa2a plus Rbv in 818 HCV-2 & HCV-3 Patients with Advanced Fibrosis and Cirrhosis
EOT SVR Rel
100
80
60
40
20
0
89 86 84
61
76
57
15
2832
Res
po
nse
rat
es (
%)
Without advanced fibrosis
Bridging fibrosis (no cirrhosis)
Cirrhosis
Bruno S et al, Hepatology 2010, 51(2):388-97
High Rates of Post-treatment Relapse in HCV-2 and 3 Patients with Advanced Fibrosis
PegIFNalfa2a + Rbv 800 mg PegIFNalfa2b + Rbv 800-1200 mg
Prati GM et al, J Hepatology 2012, 56:341-347
High Rates of Post-treatment Relapse in HCV-2 and 3 Patients with Advanced Fibrosis
Prati GM et al, J Hepatology 2012, 56:341-347
• ALT IU/L 39• HCV-RNA 105/IU/mL ND
• Total Bilirubin mg/dL 0.9• Albumin g/dL 3.9• Prothrombin ratio 1.16• Platelets 103/mmc 118
• Hb 11.8• WBC 3500• Neutrophils 1450
55ND
1.03.9
1.11147
11.541301630
573.62
0.93.9
1.16198
13.855002450
Week 4 Week 4 fupWeek 24 (EOT)
Liver Function Tests During PegIFNalfa2a 180 mcg
+ Rbv 800 mg/day anf Follow-up
Liver Function
What Now???
Retreat with PegIFN plus Rbv?
Retreat using high dose Rbv? (Off Label)
Retreat using Telaprevir? (Off Label)
Wait for new drugs? (2014-
2015)
Telaprevir Alone or in Combination With PegIFN/Rbv For HCV-2 Patients
Foster GR et al, Gastroenterology 2011, 141:881-889
Phase II study on 23 HCV-2 and 26 HCV-3 patients